BioSpace News Archive

Believes Board’s Abject Failure to Exert Sufficient Oversight of Management Has Led to Significant Stockholder Value Destruction and Must Be Immediately Addressed Adverum Is Abusing the Corporate Machinery to Entrench Incumbent Directors and Disenfranchise Stockholders

MorphoSys AG and Incyte announced the first patient has been dosed in the placebo-controlled Phase 3 inMIND study evaluating the efficacy and safety of tafasitamab or placebo in combination with lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma.

A new pivotal research paper published in the Journal of American College of Cardiology Cardiovascular Imaging presents several key validations for the clinical use of MyoStrain® in determining the risk of heart failure across multiple cardiac disease states.

PTC Therapeutics, Inc. announced that on April 13, 2021 it approved non-statutory stock options to purchase an aggregate of 75,085 shares of its common stock and 33,740 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 79 new employees.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced the company has become a member of The Skin Cancer Foundation Corporate Council.

Terumo Blood and Cell Technologies and CSL Plasma today announce a collaboration to deliver a new plasma collection platform at CSL Plasma U.S. collection centers.

Ra Medical Systems, Inc. (NYSE American: RMED) announces that it will report first quarter 2021 financial results after market close on Tuesday, May 11, 2021

The Biden Administration announced Friday a $1.7 billion investment to monitor new and emerging COVID-19 variants which could induce another pandemic wave.

SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced the appointment of Anshul Maheshwari as the company’s Chief Financial Officer effective April 20, 2021, and the addition of Helen Loh and Laura Francis to its Board of Directors effective April 18, 2021.

On April 15, 2021, ImmVira presents the preclinical study results of MVR-T3011 via intravenous administration through publication in a virtual poster at the AACR annual meeting.